F 598

Drug Profile

F 598

Alternative Names: Anti-PNAG-monoclonal-antibody; Anti-poly-N-acetyl-glucosamine-monoclonal-antibody; F598; SAR279356

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alopexx Pharmaceuticals
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Surface antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gonorrhoea
  • Phase I Tuberculosis

Most Recent Events

  • 19 Jul 2018 Phase-I clinical trials in Tuberculosis in USA (Parenteral)
  • 02 Mar 2018 Alopexx Pharmaceuticals terminates a phase II trial for Bacterial infections (due to Neisseria gonorrhoeae) (Prevention, In volunteers) in USA (IV) (NCT03222401)
  • 29 Nov 2017 Alopexx Pharmaceuticals initiates enrolment in a phase II trial for Bacterial infections (due to Neisseria gonorrhoeae) (Prevention, In volunteers) in USA (IV) (NCT03222401)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top